An observational study in Chronic Obstructive Pulmonary Disease (COPD) and Pulmonary Hypertension, sponsored by Medical University of Graz. Recruiting at 3 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-14.
Sponsored by Medical University of Graz · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 96 studies in Pulmonary Disease, Chronic Obstructive with a site in Austria — 14 open to participants now, 20 under way, 3 of them phase 3. Pulmonary Disease, Chronic Obstructive · Austria.
Among the 96 studies in Pulmonary Disease, Chronic Obstructive with a site in Austria, this one is the 5th largest by planned enrollment of the 12 observational ones that give a count, is one of 5 that started in 2025, is one of 13 observational ones, reaches primary completion later than 9 of the 19 other live ones, and was the 94th registered.
5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →14 of the 96 studies in Pulmonary Disease, Chronic Obstructive with a site in Austria are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Austria, United States, Argentina and 15 more countries
Ages 40–75
Sanofi · Sites in Austria, United States, Argentina and 19 more countries
Ages 40–85
Apreo Health, Inc. · Sites in Austria, United States, Germany and 2 more countries
Ages 40–84
GlaxoSmithKline · Sites in Austria, United States, Argentina and 13 more countries
Ages 40–80
Morair Medtech, LLC · Sites in Austria, Germany, Netherlands
Ages 40+
A study can be open while its sites in Austria have not opened yet or have stopped. Only those recruiting at a site in Austria →
Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
96 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 6 · Phase 3 40 · Phase 4 14
First in 2000; this study’s year is marked. 5 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,000 is above the median of 159 across 1,498 observational studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 304 across the 83 interventional studies, 877 across the 12 observational. Of the 66 that completed or were terminated, 44 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
76 of 96 have an industry lead sponsor. The 10 most frequent:
Medical University of Graz is the lead sponsor of 471 studies on the registry; 98 are open to participants now.
Medical University of Graz has 2 studies filed under Pulmonary Disease, Chronic Obstructive — fewer than ten, so there is no comparison to draw.
5 of the studies in Pulmonary Disease, Chronic Obstructive with a site in Austria that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05878769Phase 3Hoffmann-La RocheA Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD) | 2027-06-30 |
| NCT07102823Medical University of GrazClinical Registry for the Characterization of the 'Pulmonary Vascular Phenotype' in Patients With Chronic Obstructive Pulmonary Disease | 2026-12-30 |
| NCT05008081Wim JanssensThe CATALINA Study | 2027-03 |
| NCT06035120Pulmonx CorporationAn Evaluation of the AeriSeal System for CONVERTing Collateral Ventilation Status in Patients With Severe Emphysema | 2027-06-30 |
| NCT06891755Apreo Health, Inc.Bronchoscopic RElease of Air Trapped in Hyperinflated Emphysematous Lung - Study 3 | 2027-09-30 |
Add all 5 to your calendar (.ics) → With an account.
Among the 96 studies in Pulmonary Disease, Chronic Obstructive with a site in Austria, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Registry of COPD (Chronic Obstructive Pulmonary Disease) patients who underwent right heart catheterization (RHC) and full clinical evaluation for pulmonary hypertension
COPD patients who underwent RHC
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Severe Pulmonary Hypertension (PH)
pulmonary vascular resistance \> 5 WU (Wood Units)
Time frame: at inclusion
all-cause mortality
all-cause mortality
Time frame: Until 2026
Started Sep 2025 (actual). Primary completion is estimated for Dec 2026, 15 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pulmonary Disease, Chronic Obstructive →